FORMULATION AND EVALUATION OF SORAFENIB TOSYLATE IMMEDIATE RELEASE FILM COATED TABLETS FOR RENAL CANCER
Dr. T. Mangilal*, M. Satish Kumar, M. Ravi kumar, I. Nagaraju, L. Thirupathi and P. Veeresh kumar
ABSTRACT
Developing new drug delivery techniques is essential for
pharmaceutical companies in product development to improve safety,
efficacy and patient compliance. Immediate release drug formulation is
a novel type of drug delivery system which disintegrates rapidly and
gets dissolved to release the medicaments after administration.
Sorafenib is kinase inhibitors, used to treat renal cell carcinoma. Our
work involves the formulation, optimization and post compressed
evaluation studies of immediate release sorafenib tablets. The Wet
granulation method was employed for formulating tablets. Tablet
composition contains sorafenib tosylate, lactose monohydrate as a
filler, lycatab as disintegrate, HPC LH 11 as a binder, sodium steayl
fumarate as a lubricant and sodium dodecyl sulfate as a surfactant. The prepared tablets were
evaluated for physico-chemical properties and post evaluation studies such as drug content,
assay and in vitro dissolution. Furthermore, stability studies were conducted to know the
elements of drug decomposition. Finally, it was concluded that all the pre-formulation and
post compression studies of sorafenib tablet met with required specifications and also showed
comparably a good rate of dissolution like that of a commercial product, NEXAVAR.
Keywords: Immediate release tablet, Renal cancer, Sorafenib tosylate.
[Download Article]
[Download Certifiate]